These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 31951777)

  • 1. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
    Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.
    Michels RE; de Fransesco M; Mahajan K; Hengstman GJD; Schiffers KMH; Budhia S; Harty G; Krol M
    Appl Health Econ Health Policy; 2019 Dec; 17(6):857-873. PubMed ID: 31444659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
    Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
    Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.
    Noon KM; Montgomery SM; Adlard NE; Kroes MA
    J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
    Spelman T; Herring WL; Acosta C; Hyde R; Jokubaitis VG; Pucci E; Lugaresi A; Laureys G; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Ozakbas S; Alroughani R; Kalincik T; Duquette P; Girard M; Petersen T; Patti F; Csepany T; Granella F; Grand'Maison F; Ferraro D; Karabudak R; Jose Sa M; Trojano M; van Pesch V; Van Wijmeersch B; Cartechini E; McCombe P; Gerlach O; Spitaleri D; Rozsa C; Hodgkinson S; Bergamaschi R; Gouider R; Soysal A; Castillo-Triviño ; Prevost J; Garber J; de Gans K; Ampapa R; Simo M; Sanchez-Menoyo JL; Iuliano G; Sas A; van der Walt A; John N; Gray O; Hughes S; De Luca G; Onofrj M; Buzzard K; Skibina O; Terzi M; Slee M; Solaro C; Oreja-Guevara ; Ramo-Tello C; Fragoso Y; Shaygannejad V; Moore F; Rajda C; Aguera Morales E; Butzkueven H
    J Med Econ; 2024; 27(1):109-125. PubMed ID: 38085684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States.
    Chirikov V; Ma I; Joshi N; Patel D; Smith A; Giambrone C; Cornelio N; Hashemi L
    Value Health; 2019 Feb; 22(2):168-176. PubMed ID: 30711061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.